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OBJECTIVE — To compare fenoﬁbric acid (FA)  statin to respective monotherapies on the
prevalence of metabolic syndrome and its diagnostic components in patients with mixed
dyslipidemia.
RESEARCH DESIGN AND METHODS — Post hoc analysis of over 2,000 metabolic
syndrome patients administered either FA  low- or moderate-dose statin; FA alone; or low-,
moderate-, or high-dose statin alone.
RESULTS —F A low-ormoderate-dosestatincombinationtherapyreducedthepresenceof
metabolic syndrome (35.7 or 35.9%, respectively) more than low-, moderate-, or high-dose
statin monotherapy (15.5, 16.6, or 13.8%, respectively), mostly due to improvements in tri-
glycerides and HDL cholesterol levels. Mean glucose levels slightly decreased with FA mono-
therapy, slightly increased with statin monotherapy, and were essentially unchanged with FA 
statin. FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total
cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.
CONCLUSIONS —F A statininpatientswithmixeddyslipidemiareducestheprevalence
of metabolic syndrome.
Diabetes Care 33:2113–2116, 2010
F
enoﬁbric acid (FA) is the active moi-
etyoffenoﬁbrate.Previousstudies—
including over 2,600 patients—
support the safety and efﬁcacy of a
choline salt formulation of FA (ABT-335,
Trilipix; Abbott, North Chicago, IL) as
monotherapy or in combination with
statins (1–4). This post hoc analysis of
mixed dyslipidemic patients with meta-
bolic syndrome compared the effects of
FA combined with statins versus the indi-
vidual monotherapies on the presence of
metabolic syndrome, as well as on the in-
dividual diagnostic components of meta-
bolic syndrome.
RESEARCH DESIGN AND
METHODS— Three similarly de-
signed, phase III, randomized, double-
blind, 12-week studies evaluated the
efﬁcacy and safety of FA in combination
with either rosuvastatin (3), simvastatin
(4), or atorvastatin (2). After a 6-week
lipid-altering drug washout period, all
studies enrolled patients with mixed dys-
lipidemia (HDL cholesterol 40 mg/dl
[1.04 mmol/l] for men, 50 mg/dl
[1.30 mmol/l] for women; triglycerides
[TGs] 150 mg/dl [1.70 mmol/l]; and
LDL cholesterol 130 mg/dl [3.37
mmol/l]). Patients were assigned in a 2:2:
2:2:2:1 ratio to 1 of 6 treatment arms: FA
135 mg monotherapy; low-dose statin
monotherapy; FA 135 mg  low-dose
statin; moderate-dose statin mono-
therapy; FA 135 mg  moderate-dose
statin; or high-dose statin monotherapy.
Eachstudyusedadifferentstatin,andthe
respective doses of low-, moderate-, or
high-dosestatinwererosuvastatin10,20,
or 40 mg, or simvastatin or atorvastatin
20,40,or80mg.Datawerepooledacross
the3studies.Forfurtherdetailsregarding
patients and study design, see the article
by Jones et al. (5).
Assessments included the number
and percent of patients with metabolic
syndrome (6) at the ﬁnal visit for each
treatment group, as well as the number
and percent of patients having individual
metabolic syndrome diagnostic criteria at
the baseline visit and at the ﬁnal visit. In
ordertobeincludedintheseanalyses,pa-
tients were required to have a ﬁnal visit
value for each metabolic syndrome diag-
nostic criteria. Waist circumference was
notmeasuredatﬁnalvisit;baselinevalues
were carried forward.
Mean changes from baseline to ﬁnal
value in weight, blood pressure, and fast-
ing glucose were analyzed using a one-
way ANOVA, comparing combination
therapy with corresponding-dose mono-
therapies. Percent changes in efﬁcacy
parameterswerecomparedbetweencom-
binationtherapyandcorresponding-dose
monotherapies as previously described
(2–4).
RESULTS
Baseline characteristics
Baseline data for all ﬁve metabolic syn-
drome criteria were available for 2,654
treated patients, and 2,190 (82.5%) pa-
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 2113Table1—Prevalenceofeachmetabolicsyndromecriterionatthebaselinevisitandattheﬁnalvisit,andchangesfrombaselinetotheﬁnalvisit
in metabolic syndrome parameters
Fenoﬁbric
acid
Low-dose
statin
Moderate-
dose statin
High-dose
statin
Fenoﬁbric acid 
low-dose
statin
Fenoﬁbric acid 
moderate-dose
statin
Prevalence of each metabolic
syndrome criterion
n* 354 361 367 189 375 357
Low HDL cholesterol
Met criterion at BL† (n %) 321 (90.7) 319 (88.4) 325 (88.6) 168 (88.9) 331 (88.3) 315 (88.2)
Met criterion at ﬁnal (n %) 193 (54.5) 262 (72.6) 265 (72.2) 141 (74.6) 202 (53.9) 186 (52.1)
Elevated TG
Met criterion at BL† (n %) 332 (93.8) 342 (94.7) 338 (92.1) 171 (90.5) 356 (94.9) 340 (95.2)
Met criterion at ﬁnal (n %) 194 (54.8) 265 (73.4) 240 (65.4) 115 (60.8) 124 (34.8) 126 (35.3)
Elevated blood pressure
Met criterion at BL (n %) 269 (76.0) 266 (73.7) 289 (78.7) 140 (74.1) 294 (78.4) 266 (74.5)
Met criterion at ﬁnal (n %) 257 (72.6) 253 (70.1) 271 (73.8) 132 (69.8) 279 (74.4) 253 (70.9)
Elevated fasting glucose
Met criterion at BL (n %) 211 (59.6) 218 (60.4) 222 (60.5) 119 (63.0) 222 (59.2) 211 (59.1)
Met criterion at ﬁnal (n %) 197 (55.6) 219 (60.7) 236 (64.3) 126 (66.7) 212 (56.5) 207 (58.0)
Increased waist circumference
Met criterion at BL (n %) 300 (84.7) 285 (78.9) 290 (79.0) 158 (83.6) 289 (77.1) 277 (77.6)
Met criterion at ﬁnal‡ N/A N/A N/A N/A N/A N/A
Changes () in metabolic syndrome
parameters
HDL cholesterol
n 346 358 352 186 356 343
BL mean, mg/dl (mmol/l) 38.3 (1.0) 37.7 (1.0) 38.1 (1.0) 37.8 (1.0) 38.1 (1.0) 37.9 (1.0)
Mean SEM (%) 17.5  1.06 7.6  1.04 9.2  1.05 8.0  1.42 18.3  1.04§ 18.7  1.06§
TG
n 377 373 382 199 394 373
BL mean, mg/dl (mmol/l) 284.4 (3.2) 295.7 (3.3) 292.5 (3.3) 284.0 (3.2) 284.9 (3.2) 296.8 (3.4)
Mean SEM (%) 33.3  1.43 21.7  1.43 26.4  1.42 29.3  1.94 45.4  1.40§¶ 45.8  1.44§¶
Blood pressure
n 387 379 391 201 403 383
Systolic
BL mean (mmHg) 127.8 126.9 128.2 127.8 128.7 126.8
Mean SD (mmHg) 1.9  14.14 1.5  13.25 1.2  13.47 1.5  14.34 3.0  13.23 1.2  13.47
Diastolic
BL mean (mmHg) 78.6 78.6 79.9 79.0 79.3 78.7
Mean SD (mmHg) 1.5  8.84 0.9  9.01 1.3  8.67 1.1  8.42 2.7  9.24§ 1.6  9.42
Fasting blood glucose
n 386 379 390 201 401 381
BL mean, mg/dl (mmol/l) 108.0 (6.0) 108.3 (6.0) 106.1 (5.9) 106.8 (5.9) 107.6 (6.0) 107.1 (5.9)
Mean SD, mg/dl (mmol/l) 1.9  22.80#
(0.1  1.27)
4.7  20.68
(0.3  1.43)
4.7  17.38
(0.3  0.96)
4.8  20.68
(0.3  1.15)
0.0  19.56§
(0.0  1.09)
0.2  18.19§
(0.0  1.01)
Waist circumference
n 399 386 395 205 409 396
BL mean (cm) 105.4 105.4 105.3 105.6 104.5 104.5
Mean SD‡ N/A N/A N/A N/A N/A N/A
Metabolic syndrome was deﬁned as 3 or more of the following 5 criteria: HDL-C, 40 mg/dl (1.04 mmol/l) for men, 50 mg/dl (1.30 mmol/l) for women; TG,
150 mg/dl (1.70 mmol/l); blood pressure, 130 mmHg systolic or 85 mmHg diastolic or receiving treatment for hypertension; fasting glucose, 100 mg/dl
(5.55 mmol/l) or medical history of type 2 diabetes; waist circumference, 102 cm for men, 88 cm for women. Fasting blood glucose analyses included patients
concomitantly using medication for type 2 diabetes. *For prevalence analyses, only patients with metabolic syndrome at baseline who had both baseline and ﬁnal
visit values for the criteria were included. †Although the HDL cholesterol and TG criteria were required entry criteria for participation in the studies, not all patients
met these criteria at baseline because the lipid eligibility values were measured at the screening visit 1 week prior to randomization, while baseline lipid values
occurred the day of randomization. ‡Waist circumference was measured at baseline, but not at the ﬁnal visit. Therefore, baseline waist circumference values were
carried forward to the ﬁnal visit. §Statistically signiﬁcant difference vs. corresponding-dose statin monotherapy (P  0.001 for both HDL cholesterol and TG
comparisons, P  0.01 for all other comparisons noted). ¶Statistically signiﬁcant difference vs. fenoﬁbric acid monotherapy (P  0.001). #Statistically signiﬁcant
difference vs. statin monotherapy (P  0.001). BL, baseline.
Fenoﬁbric acid  statin in metabolic syndrome
2114 DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 care.diabetesjournals.orgtients had metabolic syndrome at base-
line. The percent of patients with
metabolic syndrome at baseline was gen-
erally similar within each of the 6 treat-
ment groups and ranged from 79.9%
(low-dose statin) to 85.8% (high-dose
statin). Across all treatment groups, 569
(26%) had a diagnosis of type 2 diabetes
(supplemental appendix A, available
in the online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc10-0357/DC1), and 461 (21.1%) re-
ceivedtreatmentwithatleast1antidiabetes
drug.
Metabolic syndrome analyses
Of the 2,190 patients in the metabolic
syndromesubgroup,2,003patientshada
ﬁnal visit value for all metabolic syn-
drome criteria (with the exception of
waist circumference since baseline values
were carried forward). Following 12
weeksoftherapyinthe3trials,FAlow-
or moderate-dose statin reduced the
number of patients meeting the diagnos-
tic criteria for metabolic syndrome by
35.7 and 35.9%, respectively, compared
with monotherapy with low-, moderate-,
or high-dose statin (15.5, 16.6, and
13.8%, respectively). FA alone reduced
metabolic syndrome diagnosis by 25.7%.
The percent of patients at baseline
who met each individual metabolic syn-
drome criterion was comparable among
alltreatmentgroups(Table1).Attheﬁnal
visit, FA  statin substantially reduced
theprevalenceofthemetabolicsyndrome
diagnostic criteria regarding HDL choles-
terolandTGcomparedwithstatinmono-
therapy. The prevalence of the blood
pressure metabolic syndrome criteria de-
creased slightly at the ﬁnal visit in each
treatment group. At the ﬁnal visit, the
prevalence of the fasting blood glucose
criterion was decreased slightly following
treatment with FA monotherapy or FA 
statin but increased slightly in the statin
monotherapy groups.
Additional efﬁcacy in the metabolic
syndrome subgroup
Regarding metabolic syndrome-associated
lipid parameters, FA  low- or moderate-
dose statin signiﬁcantly decreased TG
compared with FA or corresponding-
dosestatinmonotherapy(P0.001)and
signiﬁcantly increased HDL cholesterol
(P  0.001) compared with correspond-
ing-dose statin (Table 1). FA  low- or
moderate-dosestatinalsoresultedinsim-
ilar or greater reductions in non-HDL
cholesterol, apolipoprotein B, total cho-
lesterol, VLDL cholesterol, or high-
sensitivity C-reactive protein compared
with corresponding-dose statin (supple-
mental appendix B).
The mean changes in glucose were
slightly increased in all statin mono-
therapy groups but were slightly de-
creasedintheFAmonotherapygroupand
essentially unchanged in the FA  statin
groups. Mean increases in glucose with
statin monotherapy ranged from 2.26
mg/dl(0.13mmol/l)inthesimvastatin20
mg group to 7.46 mg/dl (0.41 mmol/l) in
the atorvastatin 20 mg group. The mean
changeinfastingglucosewassigniﬁcantly
different comparing FA  low- or mod-
erate-dose statin with low- or moderate-
dose statin monotherapy, respectively
(P  0.002). Overall, 54 (2.5%) of 2,190
patients in the metabolic syndrome sub-
group initiated new antidiabetes medica-
tion during the study; percentages were
similar among treatment groups. Mean
changes in body weight ranged from
0.3 kg in the FA monotherapy group to
0.3kgintheFAmoderate-dosestatin
group. Safety results in this metabolic
syndrome subgroup were consistent with
those observed in the overall population
(7) (supplemental appendix C).
CONCLUSIONS— This analysis is
the ﬁrst to report the effects of ﬁbrate and
statin combinations versus their respec-
tive monotherapies on the individual di-
agnostic components of metabolic
syndrome. According to this subgroup
analysis, the greatest reduction in the
presenceofmetabolicsyndromeoccurred
with the FA  statin combination, pri-
marily because of the improvements in
the TG and HDL cholesterol diagnostic
components. Although waist circumfer-
ence was not measured at the end of the
study, the lack of signiﬁcant weight
change in this study made it unlikely that
changes in the waist circumference com-
ponent altered the presence of metabolic
syndrome.
Mean glucose levels rose with statins,
but this effect was not statin-speciﬁc nor
diditappeartobedose-related.Thecom-
bination of FA with statins resulted in es-
sentially no change in fasting blood
glucose, similar to a recent report in type
2 diabetic patients (8), suggesting the
possibilitythatFAmayhavemitigatedthe
glucose-raising effect of statins. In sum-
mary, in this analysis of patients with
mixed dyslipidemia and metabolic syn-
drome, FA combined with statins pro-
duced greater improvement in multiple
metabolic parameters and in the percent
of patients meeting diagnostic criteria for
metabolic syndrome compared with ei-
ther agent alone.
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